Advancements in gene therapies targeting mutant KRAS in cancers.

Abstract excerpt

Mutations in the KRAS gene are well-known tumourigenic drivers of colorectal, pancreatic and lung cancers. Mechanistically, these mutations promote uncontrolled cell proliferation and alter the tumour microenvironment during early carcinoma stages. Given their critical carcinogenic functions, significant progress has been made in developing KRAS inhibitors for cancer treatment. However, clinical applications of...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to KRAS gene
• Share to Genetic Therapy
• Share to Molecular Targeted Therapy